An open-label,multi-centre,non-randomised phase I dose-escalation study of ONO-4059 given as monotherapy in patients with relapsed/refractory B-NHL and CLL

Trial Profile

An open-label,multi-centre,non-randomised phase I dose-escalation study of ONO-4059 given as monotherapy in patients with relapsed/refractory B-NHL and CLL

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2016

At a glance

  • Drugs Tirabrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 15 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top